Vasohibin inhibits angiogenic sprouting in vitro and supports vascular maturation processes in vivo by Kern, Johann et al.
BioMed  Central
Page 1 of 11
(page number not for citation purposes)
BMC Cancer
Open Access Research article
Vasohibin inhibits angiogenic sprouting in vitro and supports 
vascular maturation processes in vivo
Johann Kern1, Michael Steurer2, Günther Gastl1, Eberhard Gunsilius†1 and 
Gerold Untergasser*†1
Address: 1Division of Internal Medicine V, Tumor Biology & Angiogenesis Laboratory, Medical University Innsbruck, Innrain 66, A-6020 
Innsbruck, Austria and 2Division of Internal Medicine V, Laboratory for Molecular Genetics, Medical University Innsbruck, Anichstrasse 35, A-
6020 Innsbruck, Austria
Email: Johann Kern - johann.kern@i-med.ac.at; Michael Steurer - michael.steurer@i-med.ac.at; Günther Gastl - guenther.gastl@i-med.ac.at; 
Eberhard Gunsilius - eberhard.gunsilius@i-med.ac.at; Gerold Untergasser* - gerold.untergasser@i-med.ac.at
* Corresponding author    †Equal contributors
Abstract
Background: The murine homologue of human vasohibin (mVASH1), a putative antiangiogenic
protein, was investigated for its effects on in vitro and in vivo angiogenesis.
Methods: Cell growth and migration were analyzed in murine fibroblasts, smooth muscle cells and
endothelial cells. Angiogenic sprouting was studied in human umbilical vein endothelial cells
(HUVECs) in the spheroid sprouting assay. In vivo effects on blood vessel formation were
investigated in the chorioallantoic membrane (CAM) assay and in the C57BL/6 melanoma xenograft
model.
Results: Purified murine and human VASH1 protein induced apoptosis of murine fibroblasts in
vitro, but not of vascular aortic smooth muscle cells (AoSMC) or endothelial cells. Adenoviral
overexpression of murine and human VASH1 inhibited capillary sprouting of HUVECs in the
spheroid assay. Administration of recombinant murine and human VASH1 inhibited growth of large
vessels in the CAM assay and promoted the formation of a dense, fine vascular network. Murine
VASH1-overexpressing B16F10 melanomas displayed a reduction in large vessels and vascular area.
Moreover, tumors showed more microvessels that stained positive for the mural cell markers α-
smooth muscle cell actin (ASMA) and proteoglycan (NG2).
Conclusion: Our data imply that murine VASH1 causes angiogenic remodelling by inhibiting
angiogenic sprouting and large vessel growth, thereby supporting the formation of a vascular bed
consisting predominantly of mature microvessels.
Background
The human vasohibin 1 protein (hVASH1) has been pos-
tulated as an important negative feedback inhibitor of
VEGF signaling and is thus a novel candidate for antiang-
iogenic therapies [1,2]. Despite the high degree of conser-
vation and homology (>90%) of the vertebrate VASH1
gene, mouse and chicken have a shorter 289 aa protein
lacking the N-terminal 76 aa (HomoloGene # 8941; http:/
/www.ncbi.nlm.nih.gov).  Vasohibin-1  (hVASH1) tran-
scription in human endothelial cells has been shown to
be upregulated by vascular endothelial growth factor
(VEGF) [2,3], one of the key players in angiogenic proc-
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esses [4]. The hVASH1 protein harbors a putative nuclear
localization sequence, but has no signal peptide sequence
within its 76 aa N-terminus. Thus, transfected cells show
a cytoplasmic and nuclear accumulation of the protein
under standard culture conditions [5]. Moreover, a shorter
variant lacking the C-terminus (hVASH1B) has been iden-
tified in human endothelial cells [6]. This hVASH1B iso-
form has been shown to be a potent antiangiogenic
protein in in vitro and in vivo angiogenesis assays [5]. The
VASH1 gene seems to be expressed in a variety of tissues
and organs during embryogenesis of mouse and chicken
[7]. In particular, high transcriptional activity was found
in the developing brain, eye, ear and joints. Hitherto,
function of the shorter murine VASH-1 protein has not
been studied.
In this study we analyzed whether the lack of the N-termi-
nal protein domain affects angiogenic/antiangiogenic
function. Due to the lack of specific and sensitive antibod-
ies directed against murine VASH1 we generated a FLAG-
tagged protein for detection of the recombinant protein
after adenoviral or transposon-based overexpression. The
affinity-purified recombinant FLAG-tag protein was tested
in the angiogenic sprouting assay and the chicken chorio-
allantoic membrane assay. Moreover, overexpression of
mVASH1 was analyzed in endothelial cells and in the
B16F10 mouse melanoma model to study inhibitory
effects on tumor growth and vascularization.
Methods
Cell culture
The murine B16F10 melanoma cell line was purchased
from ATCC (American Type Culture Collection). Cells
were grown in RPMI 1640 supplemented with 10% fetal
calf serum, 1 × 105 IU/L penicillin, 100 mg/L streptomy-
cin, 2-mmol/L glutamine in the presence of 5% CO2.
Mouse vascular aortic smooth muscle cells (mASMC)
were purchased from Dominion Pharmakine and culti-
vated in DMEM (Gibco BRL) with 10% fetal calf serum.
Mouse embryonic fibroblasts (mFB) obtained from C129
mice were cultivated in IMDM (Gibco BRL) containing
10% fetal calf serum. HUVECs were isolated and propa-
gated as described elsewhere [8]. Human microvascular
endothelial cells (HMECs) were isolated from foreskin tis-
sue according to the protocol of the CD31 Microbead Kit
(Miltenyi Biotech) after overnight digestion in dispase II
followed by a 1 h digestion step in collagenase I (both
Sigma Biochemicals). All endothelial cells were cultured
in EGM-2 (Cambrex) on type I collagen (Sigma-Aldrich)
coated flasks.
Cloning and generation of mVASH1 expression constructs
The  mVASH1  cDNA was cloned from a mouse brain
library of C57BL/6 mice by specific primers to exon 1 (for:
5-GTCAAGCTTACTGCCAGTGGATGAG) and exon 7 (rev:
5-TTATCTAGACACCCGGATCTGGTAC) of the genomic
reference sequence on chromosome 12 (NT 039551.7).
The amplified cDNA was subcloned in the pCRScript vec-
tor (Stratagene), and the nucleotide sequence verified by
double strand sequencing. The cloned mVASH1  cDNA
corresponded to the clone NM_177354 of the NCBI Ent-
rez Nucleotide Data base http://www.ncbi.nlm.nih.gov.
Due to the lack of specific antibodies against murine
VASH1 the cDNA was cloned in frame with a short FLAG-
tag (p3xFLAG CMS-14 vector, Sigma Biochemicals). This
tag allows sensitive and specific detection of fusion pro-
teins.
Western/Dot Blot analysis
Cells were harvested and lysed in a buffer containing 10
mM Tris-HCl, pH 7, 0.2% Triton X-100 and protease
inhibitors (Complete Mini EDTA-free; Roche Applied Sci-
ence). Total protein (20 μg) was separated on 4%–20%
SDS-PAGE and transferred to an Immuno-Blot™ polyvi-
nylidene difluoride (PVDF) membrane (Bio-Rad). After
blocking the membrane in 3% skim milk powder/PBS, it
was probed with primary antibodies directed against
FLAG-tag (0.1 μg/mL, Sigma Biochemicals, mouse mono-
clonal), human vasohibin (1 μg/mL, R&D systems, goat
polyclonal anti human VASH1), carbonic anhydrase IX
(CA9, 2 μg/mL, Santa Cruz Biotechnology, goat polyclo-
nal anti human CA9), vascular endothelial growth factors
(1  μg/mL, R&D systems, goat polyclonal anti mouse
VEGF) or tubulin alpha (0.1 μg/mL, Sigma Biochemicals,
mouse monoclonal anti human tubulin) and then
detected with a 1: 2,500 dilution of an HRP-conjugated
rabbit anti-mouse IgG or a 1:2,500 dilution HRP-conju-
gated rabbit anti-goat IgG. After washing, a chemolumi-
nescent substrate (Super Signal West dura extended,
Pierce) was added to the membrane, which was then
exposed to the ECL Hyperfilm (GE Healthcare; Amersham
Biosciences).
For Dot Blot analysis 1 μg total protein was spotted on a
nitrocellulose membrane (BioRad). Blocking and detec-
tion were performed as described for the Western Blot.
Purification of recombinant protein
Recombinant Flag-tagged mVASH1 was purified from
cytosolic extracts according to the manufacturer's instruc-
tions using liquid chromatography columns and anti-
FLAG M2 agarose beads (all SIGMA Biochemicals). The
purified protein was quantified with a standardized FLAG-
BAP fusion protein (SIGMA Biochemicals) by Western
Blot analysis on the Chemidoc XRS using Quantity One
software (BioRad). Human VASH1 (VASH1A, 365 aa) was
produced and purified as described elsewhere [5].
Adenoviruses
Replication-defective adenoviruses were generated with
the AdEasy adenoviral vector system (Stratagene) accord-
ing to the manufacturer's instructions. In brief, theBMC Cancer 2009, 9:284 http://www.biomedcentral.com/1471-2407/9/284
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mVASH1-FLAG cDNA was subcloned in the pShuttle CMV
GFP-1 vector. Recombinant adenoviral DNA was gener-
ated in BJ5183 bacteria cells by means of a double-recom-
bination event between co-transformed adenoviral
backbone plasmid vector, pAdEasy-1, and a shuttle vector
carrying the gene of interest. For generation of replication-
defective adenovirus recombinant DNA was transfected
into HEK293 cells by Lipofectamin 2000 (Invitrogen),
after which cytosolic extracts were prepared. The human
VASH1- and GFP-overexpressing adenoviruses were gen-
erated as described elsewhere [5,9]. All viral titres were
determined by qPCR for the gene coding for the encapsu-
lation signal (for:5-cgacggatgtggcaaaagt, rev: 5-cctaaaac-
cgcgcgaaaa) and the respective viral plasmid DNA
standards.
Flow cytometry
Cells were incubated with 10 nM solutions of the purified
proteins and apoptosis and cell viability determined after
48 h. In brief, cells were detached by means of trypsin and
then stained with FITC-labelled Annexin-V and 7-AAD
(Beckman Coulter). After washing, cells were analyzed in
a Cytomics-FC-500 cytometer using Cytomics RXP soft-
ware (Beckman Coulter).
Cell migration assay: Scratch assay
Cells were seeded into 6-well cell culture plates. Once at
confluence, cells were serum-starved in medium contain-
ing 0.5% FCS over night, and then scratch injury was
applied using a disposable pipette tip or rubber cell
scraper (1-mm width). After injury, the monolayer was
gently washed with PBS, and the medium was replaced
with medium containing 1% FCS and 10 nM purified pro-
teins or control FLAG-tag purified extract. Cell migration
from the edge of the injured monolayer was examined
and photographed 6 hours after scratching. Migrated cells
were counted in 10 randomly selected high-power fields
(HPF) adjacent to the scratch injury and were expressed as
cells/mm2.
Spheroid sprouting assay
The assay was performed as described elsewhere [10] with
following modifications. HUVEC spheroids where gener-
ated overnight in hanging-drop culture consisting of 400
cells in EBM-2 medium, 2% FCS and 20% methylcellu-
lose (Sigma Biochemicals). Spheroids were embedded in
collagen type I from rat tail (BD) and stimulated with 25
ng/mL bFGF (Immunotools) or VEGF165  (Sigma Bio-
chemicals) in the presence or absence of 10 nM purified
recombinant proteins. Adenoviral transfection was per-
formed 48 h before embedding of the spheroids to allow
robust expression of the gene of interest.
BrDU-incorporation assay
Five thousand cells/well were seeded in triplicates into a
96 well plate (Nunc) in culture medium and were allowed
to adhere overnight before the culture medium was
changed. Thereafter, cells were transfected with the aden-
ovirus with a multiplicity of infection (MOI) of 10 virus/
cell. After 2 day cells were pulsed for 24 h with a 10 μM
dilution of BrDU (GE Healthcare) in culture medium.
Then cells were washed, fixed and incorporated BrDU
detected by a specific ELISA (GE Healthcare) in a ELISA
reader (EL808, BioTek).
Chorioallantoic membrane assay
The chick chorioallantoic membrane (CAM) assay has been
used as an established in vivo model for screening for pro-
and antiangiogenic proteins and drugs [11]. In brief, ferti-
lized white leghorn chicken eggs (SPF eggs, each group n = 6)
were purchased from Charles River (Kiesslegg) and incu-
bated in an egg incubator at 37°C and 70% humidity (Com-
pact S84, Grumbach) for four days. Subsequently, a window
was cut in each eggshell and the underlying membrane. Eggs
were incubated again for 4 h with the windows sealed
(Durapor™ tape). Then, a Thermanox™ Ring (Nunc) was
placed on the CAM and a 10 mM Tris-Glycine solution (pH
7.4) containing the purified recombinant protein (total 30
ng) or control extracts was added. Eggs were sealed and incu-
bated for a further period of three days. Then they were
opened and the CAM with the Thermanox™ ring was ana-
lyzed and photographed under a stereomicroscope with con-
nected digital camera and flexible cold light (Olympus SZ51,
Olympus E410). Blood vessels were counted inside the ring
area (20 mm2). The allantoic vascular plexus was subclassi-
fied in large vessels (diameter > 50 μm) and microvessels
(diameter < 50 μm).
RT-PCR and qPCR
RNA was purified by cell lysis and nucleic acid extraction
using the RNeasy Kit (Qiagen). Extracted total RNA was
digested with DNAse I and then transcribed to cDNA using
oligo-dT and hexanucleotide random primers (dN6) and the
AMV-Reverse Transcriptase (all Promega). For analysis in the
quantitative PCR 20 ng of each cDNA was used, 5 μL Sybr-
green Mix (Bio-Rad) and 10 pMol of each primer: vasohibin
(mVASH1 for: 5'-cccataccaagtgtgcctac, rev: 5'-agcctctttggtcatt-
tcct), actin beta (ACTB  for: 5-aagagctatgagctgcctga; rev: 5-
tacggatgtcaacgtcacac), vascular growth factor (VEGF for: 5-
ttactgctgtacctccacc; rev: 5-acaggacggcttgaagatg), transforming
growth factor alpha (TGFA for: 5-tggctgtcctcattatcacc, rev: 5-
tgggatcttcagaccactgt), angiopoietin 2 (ANGPT2  for: 5-gag-
caaaccaccttcagaga; rev: 5-atcttctcggtgttggatga) basic fibroblast
growth factor (bFGF  for: 5-tccaagcagaagagagagga; rev: 5-
tcagtgccacataccaactg), platelet-derived groth factor beta
(PDGFB  for: 5-ttccttcctctctgcta; rev: 5-tgagctttccaactc-
gactc)and angiopoietin 1 (ANGPT1  for: 5-aaatgcgcttctat-
gctaac, rev: 5-cagctttctttgcagctttc)
Analysis was performed within 50 cycles in the Bio-Rad
iCycler (Bio-Rad). Data were collected and analyzed with
the iCycler software.BMC Cancer 2009, 9:284 http://www.biomedcentral.com/1471-2407/9/284
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Generation of VASH1-overexpressing B16F10 cells
The generated cDNA-FLAG fusion protein sequence of the
p3xFLAG-CMV14 vector (Sigma Biochemicals) was sub-
cloned in the pT2 neo CIMS vector [9]. Murine B16F10
cells were transfected with the pT2 neo CMV mVASH1
FLAG vector. Cotransfection was performed with the
pCMV SB11 vector encoding the sleeping beauty (SB)
transposase. Clones resistant to neomycin were selected
and propagated in ClonaCell medium (Stem Cell Tech-
nologies Inc.). All used VASH1-overexpressing clones
(VH#1, VH#2, VH#4), and control clones (co#10, co#11,
co#12) were analyzed for mVASH1  gene and protein
expression before in vivo use.
Mouse melanoma model
Animal experiments were performed after review and
approval by the Austrian Government and the local com-
mittee for animal studies and established standards for
animal handling. Female C57BL/6 mice, 5–6 weeks old,
were purchased from Harlan Germany. Mice were subcu-
taneously inoculated in the right flank with 1 × 106
B16F10 cells dissolved in PBS. Experiments were per-
formed using three mice per cell clone (total 18 animals).
After one week tumors were measured each day using a
caliper. After 14 days animals were sacrificed, the tumor
weight determined and cryosections prepared for immun-
ofluorescence staining. Moreover, after homogenization
of the tissue mRNA and protein were extracted from all
tumors to verify mVASH1 gene/protein expression in vivo.
Immunofluorescence staining of blood vessels
Microvessel density (MVD) has been shown to correlate
with angiogenic activity and tumor progression [12].
Thus, cryosections of B16 melanoma were prepared after
freezing the removed tumor tissue in Tissue-Tek (Sakura
Finetech) using methylbuthanol and liquid nitrogen.
Thereafter, cryosections of 5 μm were cut and fixed in ace-
tone. Sections were blocked in 3% BSA/PBS and incu-
bated with a 1 μg/mL rat anti-mouse CD31 (PECAM-1,
BD Biosciences), mouse anti-smooth muscle cell actin
(ASMA; SIGMA Biochemicals) or rabbit anti mouse prote-
oglycan NG2 (Chemicon-Millipore). Detection was per-
formed with an Alexa-488-labelled goat anti-rat
(Molecular Probes, 1 μg/mL), Texas Red-labeled goat anti-
mouse (Molecular Probes, 2 μg/mL) or TRITC-labeled
swine anti-rabbit antibody (Dako Cytomation, 4 μg/mL).
Nuclei were counterstained with DAPI (100 ng/mL,
Molecular Probes). Tumors were examined with the Axio-
vert 200 M fluorescence microscope and Axiovert software
(both Zeiss). Microvessel density (MVD; diameter < 50
μm) was determined by counting ten randomly chosen
high-power fields (HPF 200×) from each tumor. Vascular
lumens were traced and luminal areas were analyzed with
the NIH ImageJ software.
Statistical analyses
Statistical analyses were performed with GraphPad
Prism™ software for Windows. Student's t Test and the
Mann-Whitney U Test were used to study differences
between two groups. Quantitative PCR data were calcu-
lated according to the delta Ct method described by Pfaffl
et al. [13]. In brief, cDNAs of all tumor samples were nor-
malized by the internal house-keeper gene actin beta
(ACTB) and all cDNAs diluted to the same concentra-
tions. Relative gene expression for each proangiogenic fac-
tor was calculated by the delta Ct method and the use of
the mean Ct value of all control tumors (n = 9, relative
expression of 1 ± standard error of the mean).
Results
Murine VASH1 induces apoptosis in embryonic fibroblasts
Both human and mouse VASH1-FLAG protein were stably
overexpressed in murine B16F10 cells for recombinant
protein production (Figure 1a, left image). Flag-tagged
protein was purified from whole cell extracts by affinity
purification and quantified by Western Blot analysis with
a monoclonal antibody specific for the C-terminal FLAG
(Figure 1a, right image). Control FLAG extracts were gen-
erated by purifying extracts of the wild type B16F10 cells
without Flag-tag fusion protein expression, i.e. traces of
not specifically bound and eluted proteins. In addition to
the full length protein, shorter proteolytic fragments were
also purified.
Both VASH1 isoforms significantly increased cell apopto-
sis of mouse fibroblasts (Figure 1b, p < 0.05). Induction
of apoptosis was observed only in murine fibroblasts
(mFB) and not in mouse aortic smooth muscle cells
(mASMC), human umbilical vein (HUVECs), or human
microvascular endothelial cells (HMECs). Both, murine
and human VASH1 significantly inhibited cell migration
of mFB, but had no inhibitory effect on mASMC. Moreo-
ver, both vasohibins were tested on human endothelial
cells were they showed an opposite effect on short-time
cell migration (Figure 1c). Human VASH1 supported
migration and murine VASH1 inhibited migration of
human endothelial cells within 6 hours of incubation.
Due to these effects on cell migration in the scratch assay,
we tested both vasohibins in a more complex angiogenic
sprouting assay based on three-dimensional cell-cell con-
tacts and extracellular matrix degradation with proteases.
Vasohibin inhibits angiogenic sprouting of endothelial cells 
in vitro
A three-dimensional angiogenic sprouting assay in rat col-
lagen gel was performed to analyze the effect both vaso-
hibin isoforms, human and mouse on VEGF- and bFGF-
induced angiogenic sprouting. Both vascular growth fac-
tors induced strong angiogenic responses 24 h after stim-
ulation when incubated with FLAG-control extract (FigureBMC Cancer 2009, 9:284 http://www.biomedcentral.com/1471-2407/9/284
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Effects of recombinant vasohibins on cell viability of fibroblasts, smooth muscle and endothelial cells Figure 1
Effects of recombinant vasohibins on cell viability of fibroblasts, smooth muscle and endothelial cells. (A) Affinity 
purification of FLAG-tagged vasohibin proteins. Cell extracts of B16F10 cells with stable expression of human and murine 
VASH1 in comparison to wild-type cells (WT). Recombinant human and murine VASH1 proteins were analyzed by Western 
Blot after purification from cell extracts by affinity chromatography. Unspecific proteins of WT cells binding to the column are 
indicated as control. (B) Embryonic mouse fibroblasts (mFB), mouse aortic smooth muscle cells (mASMC), human umbilical 
vein (HUVEC) and microvascular endothelial cells (HMEC) were stimulated with 10 nM murine or human VASH1 protein or 
control extract (FLAG), after which apoptotic cells were counted by flow cytometry after Annexin-V/7AAD staining. 
Untreated cells were used as control. (C) Cell migration was analyzed in the scratch assay 6 h after stimulation with 10 nM 
mouse or human VASH1 or control protein. Stars indicate p values < 0.05.BMC Cancer 2009, 9:284 http://www.biomedcentral.com/1471-2407/9/284
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2a). This was not observed after application of 10 nM
murine or human VASH1 (Figure 2b). Application of
recombinant human and murine VASH1 significantly
inhibited bFGF-induced sprouting of spheroids (Figure
2c). The inhibitory effect was even more pronounced in
VEGF-treated spheroids (Figure 2d).
The intracellular effects of VASH1 were tested after adeno-
viral overexpression of mouse and human VASH1.
HUVECs showed strong expression of human and mouse
VASH1 48 h after transfection (Figure 3a). Moreover,
transfected cells were analyzed for inhibitory effects on
cell proliferation. In comparison to GFP- transfected cells,
both vasohibins did not significantly inhibit DNA synthe-
sis in HUVECs (Figure 3b). Transfected cells were used to
form spheroids and then stimulated with VEGF or bFGF
for 24 h. In comparison to GFP-transfected cells, VASH1-
transfected cells showed a reduction in bFGF- (Figure 3c)
and VEGF- (Figure 3d) induced angiogenic sprouting.
Vasohibin inhibits large-vessel growth and supports 
microvessel formation in the CAM assay
On the basis of our in vitro data in the HUVEC spheroid
sprouting assay, we decided to test the murine vasohibin
Effects of recombinant vasohibins on angiogenic sprouting of  endothelial cells Figure 2
Effects of recombinant vasohibins on angiogenic 
sprouting of endothelial cells. (A) HUVEC spheroids 
were stimulated for 24 h with VEGF and bFGF in the pres-
ence of control FLAG protein to induce angiogenic sprouting 
into the collagen gel. (B) Angiogenic sprouting was inhibited 
by administering of 10 nM recombinant murine VASH1. (C) 
Effects of recombinant human and murine VASH1 (10 nM) on 
bFGF-induced angiogenic sprouting. (D) Effects of recom-
binant human and murine VASH1 (10 nM) on VEGF-induced 
angiogenic sprouting. FLAG indicates the control extract of 
the affinity purification. CSL indicates the cumulative sprout 
length of the spheroid and stars indicate p values < 0.05.
Effects of adenoviral overexpression of vasohibins on cell pro- liferation and sprouting of endothelial cells Figure 3
Effects of adenoviral overexpression of vasohibins on 
cell proliferation and sprouting of endothelial cells. 
(A) Dot Blot analysis of VASH1 protein expression 48 h after 
adenoviral transfection of HUVECs. The used MOI was 100 
virus/cell. A monoclonal antibody directed against the FLAG-
tag (FLAG) was used to detect FLAG proteins. Tubulin alpha 
(Tub) served as internal loading control. Note: the polyclonal 
antibody directed against human VASH1 (hVASH1) does not 
recognize murine VASH1. (B) Cell proliferation was analyzed 
after adenoviral overexpression of human and human vaso-
hibins or GFP. BrDU incorporation was measured 48 h post 
transfection. (C) HUVEC spheroids were stimulated with 
bFGF to induce angiogenic sprouting two days after adenovi-
ral transfection. CSL indicates cumulative sprout length of 
the spheroid. GFP was used as control for unspecific adeno-
viral effects. (D) Angiogenic sprouting induced by the growth 
factor VEGF was significantly inhibited by VASH1 overex-
pression. Stars indicate p values < 0.05.BMC Cancer 2009, 9:284 http://www.biomedcentral.com/1471-2407/9/284
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protein in direct comparison to the human isoform in the
chicken chorioallantoic membrane (CAM) assay (Figure
4a). Application of 30 ng purified human VASH1/ring
resulted in strong inhibition of large vessel formation
after three days (p < 0.05, Figure 4b). Moreover, the
number of visible blood-conducting microvessels signifi-
cantly increased in human VASH1 treated CAMs (p <
0.05, Figure 4c). These effects were more pronounced after
application of murine VASH1.
Murine VASH1 supports microvessel maturation in the 
B16F10 melanoma model
Murine B16F10 melanoma cells with stable overexpres-
sion of mVASH1 were generated. These cells were used to
study the effects of mVASH1 on subcutaneous tumor
growth and vascularization without any immunological
interference due to overexpression of a xenoprotein. Inter-
estingly, B16F10 cells themselves have weak endogenous
VASH1 and strong VEGF and ANGPT2 gene expression
(data not shown). VASH1 overexpression was retained in
all three different cell clones (VH#1, VH#2, VH#4) clones
analyzed within 14 days of in vivo growth (Figure 5a).
Within the observed short time of two weeks, mVASH1-
overexpressing melanomas did not show a significant
decrease in tumor size (data not shown), but histologi-
cally large blood vessels with a diameter > 50 μm were
nearly absent (Figure 5b, Figure 6a). Moreover, the vascu-
lar area in the tumors was strongly reduced (Figure 5c).
Moreover, generated tumors showed immunoreactive
Flag-tagged murine VASH1 protein (Figure 5d). Hypoxic
regions in tumors were analyzed by the use of carbonic
anhydrase 9 (CA9), one of the most sensitive endogenous
sensors of HIF-1 activity. Analysis of tumor tissue revealed
an increase of CA9 protein levels in mVASH1 overexpress-
ing melanoma (figure 5d), whereas VEGF protein levels
were not significantly altered.
Moreover. proangiogenic gene expression was analyzed in
VASH1 overexpressing tumors (Figure 5e). Remarkably,
mVASH1 overexpressing tumors showed a significant
reduction of transforming growth factor -alpha (TGFA)
gene expression, whereas bFGF, VEGF, ANGPT1, ANGPT2
and PDGFB gene expression differed not significantly. The
downregulation of TGFA  gene expression was also
observed in all in vitro cultivated mVASH1 overexpressing
cell clones (data not shown).
However, when microvessels in all tumors were analyzed
with an antibody together with the mural cell markers
ASMA or NG-2 (Figure 6b), mVASH1-overexpressing
melanomas showed a significant increase in CD31+,
NG2+/CD31+ and ASMA+/CD31+ microvessels (p <
0.05; Figure 6c).
Discussion
VASH1 has been identified as a target gene of VEGF in
human umbilical vein endothelial cells [2,3]. Moreover,
the gene has been demonstrated to be strongly upregu-
lated by VEGF in the mouse retinopathy model in vivo
[14]. Despite the clear induction by VEGF, vasohibin has
been shown to inhibit in vitro and in vivo angiogenesis
Effects of recombinant VASH1 proteins on blood vessel for- mation in the CAM assay Figure 4
Effects of recombinant VASH1 proteins on blood 
vessel formation in the CAM assay. (A) Comparison of 
CAMs treated with 30 ng purified mVASH1 (n = 6), co-FLAG 
extract (n = 6) or 30 ng human VASH1 (n = 6). All blood ves-
sels within the ring area (20 mm2) were counted. (B) Reduc-
tion of large vessels (diameter > 50 μm) in human and 
murine VASH1 treated CAMs. (C) Microvessels (diameter < 
50 μm) were significantly increased in human and murine 
VASH1-treated CAMs. Stars indicate p values < 0.05. Con-
trols indicate untreated CAMs (n = 6).BMC Cancer 2009, 9:284 http://www.biomedcentral.com/1471-2407/9/284
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after exogenous application and proteolytic modification
[2,5]. Thus, it has been assumed that VASH1 functions as
a negative feedback inhibitor of angiogenesis and might
be a promising candidate structure for antiangiogenic
therapies. The mechanism of action is still unclear, but
vasohibin protein fragments might interfere in integrin/
FAK signaling or inhibit angiogenic signaling pathways by
interfering in ligand-receptor interactions. Hitherto, no
receptor binding specifically VASH1 or its fragments has
been identified. Additionally, vasohibin might be
deposed in the extracellular matrix and thereby affect
blood vessel formation and maturation [15] or be
released into the blood circulation as shown for endosta-
tin [16] and thereby inhibit angiogenic sprouting proc-
esses of endothelial cells.
This study compares the shorter murine VASH1 protein
directly with the longer human homologue for antiang-
iogenic activities in a variety of in vitro and in vivo assays.
Administration of recombinant mVASH1 neither inhib-
ited proliferation nor induced apoptosis of endothelial
cells in vitro. In line with our previous in vitro data with
human VASH1A on HUVECs [5] the unprocessed human
isoform either supported migration of human endothelial
cells  in vitro. This was not observed with the shorter
murine VASH1, that slightly inhibited cell migration of
human endothelial cells. Presumably, the N-terminal
region modulates the function of human VASH1 and
requires proteolytical removal to unmask an inhibitory
domain responsible for inhibition of cell migration.
However, both VASH1 proteins induced apoptosis and
inhibited cell migration in fibroblasts. Thus, VASH1
released from endothelial cells or cells of the immune sys-
tem [5] could inhibit fibroblast proliferation in the tumor
stroma and inhibit pro-angiogenic tissue remodeling in
the reactive stroma of the tumor and support differentia-
tion processes of mural cells.
Interestingly, exogenously applied recombinant protein
as well as intracellular overexpression of the mVASH1
gene strongly inhibited angiogenic sprouting of HUVEC
spheroids in the three-dimensional collagen gel. This
observation is a novel finding and indicates that in order
to act VASH1 needs to interact with a complex extracellu-
lar matrix, proteases and/or three-dimensional cell-cell
contacts.
Exogenous administration of recombinant murine and
human VASH1 in the CAM assay strongly induced a
remodeling of the developing embryonic allantoic vascu-
lar plexus. In comparison to controls, large vessel forma-
tion was strongly inhibited and the number of blood-
conducting microvessels was significantly increased.
These in vivo data and the in vitro observation that VASH1
inhibited spheroid sprouting processes might indicate
that VASH1 has additional functions. The protein might
acts as a morphogen in vascular remodeling by inhibiting
the formation of larger vessels in favor of a vascular bed
Effects of stable overexpression of mVASH1 on tumor  growth and large vessel growth Figure 5
Effects of stable overexpression of mVASH1 on 
tumor growth and large vessel growth. B16F10 cell 
clones with mVASH1 overexpression (VH#1, 2, 4) or con-
trol clones (co#10, 11, 12) were subcutaneously transplanted 
in C57BL/6 mice and melanomas removed after 14 days. (A) 
VASH1 gene expression was analyzed in all tumor samples by 
RT-PCR. Actin beta (ACTB) served as housekeeping gene. 
(B) Statistical analysis of large vessels (diameter>50 μm) in 
controls and mVASH1-overexpressing tumors. (C) Analysis 
of vasular area in controls and mVASH1-overexpressing 
tumors (D) Western blot analysis of tissue protein extracts 
of a VASH1 overexpressing and control melanoma. Immuno-
reactive VASH1 protein was present in high amounts and 
also carbonic anhydrase 9 (CA9) was higher expressed in 
VASH1 overexpressing melanomas. VEGF protein was not 
altered. Tubulin alpha served as internal loading control. (E) 
Proangiogenic gene expression was analyzed by qPCR in con-
trols and mVASH1-overexpressing tumors. Proangiogenic 
gene expression of VASH1 overexpressing tumors (n = 9) 
was quantified relative to the mean of all control tumors (n = 
9). Stars indicate p values < 0.05 and bars mean ± SEM.BMC Cancer 2009, 9:284 http://www.biomedcentral.com/1471-2407/9/284
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Effects of stable overexpression of mVASH1 on tumor microvessel growth and maturation Figure 6
Effects of stable overexpression of mVASH1 on tumor microvessel growth and maturation. (A) Representative 
image of CD31 stained blood vessels in controls and VASH1 overexpressing melanomas. Bars indicate 50 μm. (B) Cryosections 
of all tumors were analyzed by co-staining for the endothelial marker CD31 together with the pericyte marker NG2 or the 
smooth muscle cell marker ASMA. Bars indicate 20 μm (C) Statistical analysis of microvessels in controls and mVASH1-over-
expressing tumors. HPF indicates high power field (200×).BMC Cancer 2009, 9:284 http://www.biomedcentral.com/1471-2407/9/284
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consisting primarily of small capillaries. Whether the
observed increases of microvessels are the consequence of
collapsing large vessels or hypoxia in the CAM after
VASH1 induced destabilization of larger vessels remains
to be investigated in future studies.
Apart from its effects on physiological angiogenesis
murine VASH1 was also studied in a mouse tumor model
to analyze its effects on tumor growth and vascularization.
This was done in the B16 melanoma model, a tumor
model with a strong proangiogenic phenotype, i.e. pro-
duction and secretion of VEGF and angiopoietin-2 [17].
In agreement with Watanabe et al. [2] we found no influ-
ence on in vitro proliferation of tumor cells but a signifi-
cant reduction in large vessels and vascular area in
mVASH1-overexpressing melanomas. Simultaneously, we
observed an increase of microvessels in mVASH1-overex-
pressing tumors. This might be due to hypoxia after large
vessel regression, since Hosaka et al. observed a positive
correlation between VASH1 expression in blood vessels
and HIF-1α expression in tumor cells of human non-
small cell lung carcinoma [18]. At least in the final stages
of our melanoma we found an increases of carbonic anhy-
drase protein levels, an enzyme induced by hypoxia and a
sensor of HIF1α transcription factor activity [19]. How-
ever VEGF, an other important target of hypoxia was not
increased in the final stages of mVASH1 overexpressing
melanomas. These observations can be explained that
either hypoxia did not always provoke VEGF upregulation
in tumors [20] or that VEGF was upregulated in early
stages and normalized at later stages of tumor progres-
sion.
Moreover, microvessels were more mature, i.e. they had
more mural cell coverage as shown by costaining for per-
icytes (NG2) and smooth muscle cells (ASMA). These
observation is in line with the recent observations in
VASH1 knock-out mice, that show defects in blood vessel
maturation of Lewis lung carcinoma xenografts [18,21].
Presumably, the fast-growing subcutaneous melanoma
model prevented us from noticing a reduction in tumor
size, as Watanabe et al. [2] observed in the Lewis lung car-
cinoma xenograft model overexpressing the human
VASH1A. Therefore, the efficiency of the antiangiogenic
effect of VASH1 might strongly depend on the tumor type
analyzed. Additional tumor models have to be studied to
identify tumor types that are sensitive to an antiang-
iogenic therapy consisting of gene therapy or systemically
administered VASH1 protein or peptides.
Conclusion
Although vasohibin has been proposed to be primarily an
antiangiogenic protein, we could further demonstrate that
it acts also as a morphogen in the vessel maturation proc-
ess in vivo. Overexpression in tumor xenografts led to a
reduction of larger tumor vessels and supported the for-
mation of a dense microvessel network with more mature
vessels covered by mural cells, such as pericytes and
smooth muscle cells.
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